2 aspects to look at

The first aspect is the product...facts we know:

Crossmark will be in charge of distribution
Symbion have received orders.
Annecdotal evidence suggests thermalife is far superior to Voltarin.
The launch must be close .
Pno also has Red and savantac in the pipeline
tripeptofen is owned by PNO.

2nd aspect is about the company.
Hsitory of being a pure biotech/research company.
History of being slow
History of pump and dumps in share price.

One thing to remember is people in the marketplace will be buying thermalife not the history of the company. if thermalife works the company will make profits. profits is what drives share prices at the end of the day.

For the medium term investor pno could offer a very rewarding return against todays price.dyor